File: '\\swfile\EmailIn\20251211 152408 Attachment Asep NR Amended MD&A 12112025.docx'

Asep Medical Holdings Inc.

Asep Medical Holdings Amends and Refiles its Management's Discussion & Analysis for its Year Ended December 31, 2024

December 11, 2025 - Vancouver, British Columbia - Asep Medical Holdings Inc. ("Asep Medical" or the "Company") (CSE: ASEP; OTCQB: SEPSF; FSE: JJ8) announces that it is refiling the December 31, 2024, Management's Discussion and Analysis ("MD&A").

The amendments are summarized as follows:

Additional section inserted in the MD&A titled Intellectual Properties, which provides disclosure of the patents and licenses held by the Company's subsidiary companies, ABT Innovations Inc. ("ABT") and Sepset Biosciences Inc. ("Sepset").

Additional section inserted in the MD&A titled Additional Disclosure for Venture Issuers Without Significant Revenue, which provides disclosure of the research and development activities being conducted by ABT on its therapeutic technology and Sepset on its diagnostic technology under development.

Schedule A has been appended to the amended MD&A providing current disclosure relating to the audit committee required by Form 52-110F2.

Schedule B has been appended to the amended MD&A providing current disclosure relating to corporate governance required y Form 58-101F2.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists and the CEO of Asep. Asep holds a controlling interest in two private subsidiary companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin

Asep Medical Holdings Inc.

E. chris@asepmedical.com

T. 604-362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the successful execution of the Company's business plan, the development, testing, and commercialization of its sepsis diagnostic test (Sepset), and other statements regarding the Company's proposed business plans and technologies. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as

required by applicable law.